SMAM
VRTX icon

Sugar Maple Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Sugar Maple Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-87
Closed -$35K – 456
2024
Q4 		$35K Buy
+87
New +$40.3K 0.03% 144

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Sugar Maple Asset Management's VRTX Position: Q1 2025 in Review

Sugar Maple Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2025, closing a stake of 87 shares — an estimated $35K sold.

Sugar Maple Asset Management first reported a position in VRTX in Q4 2024 and held it in 1 quarter. The position peaked at $35K in Q4 2024. 1,613 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

  • Sugar Maple Asset Management reported no remaining Vertex Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Sugar Maple Asset Management sold 87 Vertex Pharmaceuticals shares in Q1 2025, an estimated $35K.
  • Sugar Maple Asset Management first reported a position in Vertex Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Sugar Maple Asset Management's Vertex Pharmaceuticals position peaked at $35K in Q4 2024.
  • 1,613 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on Sugar Maple Asset Management's 13F filing for Q1 2025, filed 10 Apr 2025.